Abstract Details

Title Sickle Cell Disease and Stroke: Data from the Florida Stroke Registry

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S35 - Cerebrovascular Disease: Meta-analyses and Outcomes Research (1:12 PM-1:24 PM)

Poster/Presentation
Number 002

Background

Stroke is among the most devastating consequences of SCD. Up to 24% can develop stroke by age 45, but there has not been major advancements in adult strokes with SCD.

Objective We sought to determine stroke prevalence and outcome at discharge of stroke patients with Sickle Cell Disease (SCD) from the Florida Stroke Registry.

Design/Methods

Patients with SCD were identified from the state-wide Florida Stroke Registry (FSR) comprising of 153 hospitals that use the AHA GWTG-Stroke quality improvement metric data collected during stroke hospitalization. Here we present demographics, clinical characteristics, and outcomes at discharge of SCD from the FSR.

Results

Between January 2010 and May 2021, 396,741 strokes were included in the FSR, of which 338 had SCD (59% women, age 48±18 years (range 4-93), 81% black, 12% white, 7% Hispanic, 75% ischemic stroke, 7% TIA, 12% ICH, 6% SAH). More SCD strokes occurred between ages 32-41 (19%) than any other decade, and 75% under 61 years. Compared to those without SCD, SCD patients were significantly younger (48 vs. 70), more likely to ambulate independently at discharge (54.7% vs. 40.3%), less likely to get discharged to a nursing facility (10% vs. 17%) and more likely to be discharged home (60% vs. 50%), with a trend towards better functional status at discharge (modified Rankin Score 0-2 [53% vs. 46%] and 3-5 [47% vs. 54%], p=0.07), despite similar NIHSS on presentation (median 4, p=0.9), or in-hospital mortality (6.3% vs. 5.3%%, p=0.4).

Conclusions

Adult SCD stroke patients present at a younger age, and during their most productive working age. Although patients with SCD have more favorable discharge outcomes than those without SCD, almost half of adult patients do not ambulate independently at discharge. Further research is needed on long term outcomes and the quality of systems of care for SCD patients that transition from childhood to adults.

Authors/Disclosures
Nastajjia Krementz, MD (Vascular Neurology - University of Miami/Jackson Health System) PRESENTER	Dr. Krementz has nothing to disclose.
	No disclosure on file
Carolina Gutierrez	No disclosure on file
	No disclosure on file
Negar Asdaghi, MD (University of Miami)	Dr. Asdaghi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association.
Ralph L. Sacco, MD, MS, FAHA	Dr. Sacco has received personal compensation in the range of $100,000-$499,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Sacco has received research support from NIH, NINDS, NCATS, NIMHD. The institution of Dr. Sacco has received research support from FL Department of Health. Dr. Sacco has received research support from University of Washington, Seattle. Dr. Sacco has received publishing royalties from a publication relating to health care.
Jose G. Romano, MD, FAAN (University of Miami, Miller School of Medicine)	Dr. Romano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Romano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vycor. Dr. Romano has stock in Vycor Medical/NovaVision. The institution of Dr. Romano has received research support from NIH/NINDS. The institution of Dr. Romano has received research support from NIH/NIMHHD.
Tatjana Rundek, MD, PhD	The institution of Dr. Rundek has received research support from NIH.
	No disclosure on file